Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
$58.74
-3.7%
$84.85
$58.04
$94.80
$26.94B1.143.06 million shs4.42 million shs
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$25.21
-9.2%
$39.76
$11.20
$72.98
$5.60B1.6522.90 million shs22.12 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$717.21
-0.9%
$846.64
$677.09
$972.53
$679.67B0.513.67 million shs2.83 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$61.14
-3.9%
$80.37
$60.61
$148.15
$274.25B0.618.48 million shs6.36 million shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
+0.79%-24.43%-29.56%-26.84%-31.06%
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
+6.85%-6.79%-23.07%+0.35%+90.94%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-2.11%-12.53%-16.87%-6.60%-7.93%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
+1.49%-8.72%-27.15%-23.65%-49.54%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
4.0027 of 5 stars
3.44.01.70.03.41.72.5
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
3.714 of 5 stars
4.12.00.00.02.83.31.9
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.9027 of 5 stars
3.45.03.34.03.32.51.9
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
4.4988 of 5 stars
3.45.02.50.02.80.04.4
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
2.75
Moderate Buy$97.7366.37% Upside
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
2.27
Hold$37.3147.99% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.89
Moderate Buy$1,018.8942.06% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.80
Moderate Buy$145.25137.57% Upside

Current Analyst Ratings Breakdown

Latest GEHC, LLY, NVO, and HIMS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/8/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$892.00 ➝ $888.00
4/2/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell ➝ Sell
3/18/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetUnderperform ➝ Underperform$21.00 ➝ $22.00
3/13/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Kepler Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy
3/11/2025
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$85.00 ➝ $100.00
3/6/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$1,146.00
3/6/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingUnderperform ➝ Underperform$21.00 ➝ $21.00
3/6/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell ➝ Sell$27.00 ➝ $27.00
3/5/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$970.00 ➝ $1,100.00
3/3/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
2/26/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$24.00 ➝ $39.00
(Data available from 4/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
$19.67B1.37$3.69 per share15.94$18.51 per share3.17
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$1.48B3.79N/AN/A$1.61 per share15.66
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$45.04B15.10$11.69 per share61.34$15.05 per share47.66
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$290.40B0.94$2.83 per share21.57$4.64 per share13.18
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
$1.99B$4.3313.6011.303.1910.13%25.74%6.29%4/29/2025 (Estimated)
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
-$23.55M$0.5457.2448.48N/A8.19%10.97%8.29%5/5/2025 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$11.7161.2123.051.4023.51%85.24%16.19%5/1/2025 (Estimated)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$14.64B$3.2918.5813.120.9034.81%84.68%26.29%5/7/2025 (Estimated)

Latest GEHC, LLY, NVO, and HIMS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/5/2025N/A
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$0.11N/AN/AN/A$535.21 millionN/A
5/1/2025N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$4.64N/AN/AN/A$12.77 billionN/A
5/1/2025N/A
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.92N/AN/AN/AN/AN/A
4/29/2025N/A
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
$0.91N/AN/AN/A$4.66 billionN/A
2/24/2025Q4 2024
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$0.09$0.11+$0.02$0.11$494.56 million$481.14 million
2/13/2025Q4 2024
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
$1.26$1.45+$0.19$1.57$5.33 billion$5.32 billion
2/6/2025Q4 2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.45$5.32-$0.13$4.88$13.42 billionN/A
2/5/2025Q4 2024
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.88$0.91+$0.03$0.91N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
$0.140.24%N/A3.23%N/A
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
N/AN/AN/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.84%+15.21%51.24%11 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$1.572.57%+25.26%47.72%N/A

Latest GEHC, LLY, NVO, and HIMS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/27/2025
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
quarterly$0.03500.17%4/25/20254/25/20255/15/2025
2/5/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
semi-annual$0.78741.2%3/31/20253/31/20254/8/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
0.88
1.04
0.83
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
N/A
2.14
1.82
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.00
1.15
0.97
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.62
0.74
0.55

Institutional Ownership

CompanyInstitutional Ownership
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
82.06%
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
63.52%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%
CompanyEmployeesShares OutstandingFree FloatOptionable
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
50,000457.30 million456.06 millionOptionable
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
650222.17 million179.79 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
39,000948.17 million948.08 millionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
54,4004.49 billion4.48 billionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
GE HealthCare Technologies stock logo

GE HealthCare Technologies NASDAQ:GEHC

$58.74 -2.25 (-3.69%)
As of 03:39 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, X-ray systems, and women's health products. The Ultrasound segment provides medical devices and solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring solutions, anesthesia delivery and respiratory care products, electrocardiogram solutions, maternal infant care products, and consumables and services. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. It has an AI collaboration with Mass General Brigham. The company was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.

Hims & Hers Health stock logo

Hims & Hers Health NYSE:HIMS

$25.21 -2.56 (-9.22%)
As of 03:39 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$717.21 -6.52 (-0.90%)
As of 03:39 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$61.14 -2.50 (-3.93%)
As of 03:39 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.